IssuerAnnouncementDetailsV2Portlet
Actions
Saudi Pharmaceutical Industries and Medical Appliances Corporation (“SPIMACO") announces the appointment of a member of the Audit Committee
2070
SPIMACO
-0.56
%
1445/07/19 31/01/2024 08:28:05
| Element List | Explanation |
|---|---|
| Introduction | Saudi Pharmaceutical Industries and Medical Appliances Corporation (“SPIMACO") announces the Board resolution issued on 18 Rajab 1445H corresponding to 30 January 2024 regarding the appointment of Board member Dr. Fahad Abdulaziz Alrabiah as independent member of the Audit Committee, to complete the term of the current session of the Audit Committee, which ends on April 02, 2025. |
| Element List | Explanation |
|---|---|
| Appointed Member Name | Dr. Fahad Abdulaziz Alrabiah |
| Membership Start Date | 2024-01-30 Corresponding to 1445-07-18 |
| Brief Resume of the Appointed Member | Dr. Fahad Alrabiah holds a bachelor’s degree in medicine and surgery from King Saud University, and an Arab board in Internal Medicine and a Canadian Fellowship in Infectious Diseases from the University of British Columbia. He has held numerous positions, including CEO of the Saudi Diagnostics Company Limited, He currently works as Consultant of Infectious Diseases and Virologist at King Faisal Specialist Hospital and Research Center in Riyadh, and the Vice Chairman of the Board of Directors of Al-Takhassusi international Holding Company and the Chairman of The Executive Committee and Chairman of the Resource Development Committee at the Referral Center in the Ministry of Health. |
| The date of the approval by other official authorities | Not Applicable |
| Element List | Explanation |
|---|---|
| Date of Board Meeting in which Appointed New Member(s) were Appointed | 2024-01-30 Corresponding to 1445-07-18 |
| Additional Information | None |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Share
Company Performance
SPIMACO
Add To Watchlist
In your Watchlist
Add To Watchlist
Key Parameters
Last Price 24.72
Net Change -0.14 (-0.56%)
Value Traded (Sar) 3,390,757.38
Volume Traded 136,744
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions
Complementary
Content
- ${title}${badge}
${loading}